Abstract
The development and progression of lung cancer is a multistep process characterized by the accumulation of numerous genetic and epigenetic alterations, some of which occur early in the course of disease. In this review, we summarize cytogenetic imbalances and molecular genetic/epigenetic changes seen in human small-cell and non-smallcell lung cancer. Alterations of tumor suppressor genes and oncogenes leading to perturbations of key cell-regulatory and growth-control pathways are highlighted. The translational implications of molecular biomarkers for risk assessment, early detection, and monitoring of chemoprevention trials are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 183-188 |
| Number of pages | 6 |
| Journal | American Journal of Medical Genetics, Part C: Seminars in Medical Genetics |
| Volume | 115 |
| Issue number | 3 |
| DOIs | |
| State | Published - Oct 30 2002 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cytogenetic imbalances
- Genetic/epigenetic changes
- Lung cancer
- Molecular biomarkers
- Tumor suppressor genes, oncogenes
Fingerprint
Dive into the research topics of 'Cytogenetics and molecular genetics of lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver